使用[11C]CH和[18F]FDG双示踪剂方法在肝细胞癌临床决策中的应用
本研究纳入2018年2月至2021年12月在本机构同时接受[11C]CH和[18F]FDG PET/CT的19例疑似复发或进展的肝细胞癌患者,两次显像间隔4周内且随访至少6个月。双示踪剂关键发现检出率为95%,[18F]FDG为68%,[11C]CH为84%。作者认为在高危患者或常规影像不能确定时倾向于采用双示踪剂方法进行肝细胞癌分期。
要点
- 双示踪剂关键发现检出率为95%,[18F]FDG为68%,[11C]CH为84%。
- [18F]FDG发现更多消融部位复发(5例中4例),[11C]CH为5例中2例。
- 仅[11C]CH发现两处针道转移,两种示踪剂均发现75%的阳性淋巴结。
核心结论
- 作者认为在高危患者或常规影像不能确定时,倾向于采用双示踪剂方法进行肝细胞癌分期。
研究设计与样本
- 纳入2018年2月至2021年12月在本机构同时接受[11C]CH和[18F]FDG PET/CT的肝细胞癌患者,两次显像间隔4周内且随访至少6个月。
- 共纳入19例患者,其中除6例外均曾接受肝细胞癌治疗。
- 患者因CT/MRI不明原因可疑或血清肿瘤标志物突然升高而接受双示踪剂PET/CT。
- 当发现具有预后意义并导致治疗改变时,病灶被认为是关键发现。
主要发现
- 双示踪剂关键发现检出率为95%,[18F]FDG为68%,[11C]CH为84%。
- 肝内肝细胞癌复发检出率两种示踪剂均为65%。
- [18F]FDG发现消融部位复发4/5例,[11C]CH发现2/5例。
- 仅[11C]CH发现两处针道转移。
- 两种示踪剂均发现75%的阳性淋巴结。
临床怎么用
- 作者认为在高危患者或常规影像不能确定时,倾向于采用双示踪剂方法进行肝细胞癌分期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early detection of recurrent or progressive HCC remains the strongest prognostic factor for survival. Dual tracer PET/CT imaging with [11C]CH and [18F]FDG can further increase detection rates as both tracers entail different metabolic pathways involved in HCC development. We investigated dual-tracer PET/CT in clinical decision making in patients suspected of recurrent or progressive HCC. All HCC patients who underwent both [11C]CH and [18F]FDG PET/CT in our institute from February 2018 to December 2021 were included. Both tracer PET/CT were within 4 weeks of each other with at least 6-month follow-up. Patients underwent dual tracer PET/CT because of unexplained and suspicious CT/MRI or sudden rise of serum tumour markers. A detected lesion was considered critical when the finding had prognostic consequences leading to treatment changes. RESULTS: Nineteen patients who underwent [11C]CH and [18F]FDG PET/CT were included of which all but six patients were previously treated for HCC. Dual-tracer critical finding detection rate was 95%, with [18F]FDG 68%, and [11C]CH 84%. Intrahepatic HCC recurrence finding rate was 65% for both tracers. [18F]FDG found more ablation site recurrences (4/5) compared to [11C]CH (2/5). Only [11C]CH found two needle tract metastases. Both tracers found 75% of the positive lymph nodes. Two new primary tumours were found, one by [18F]FDG and both by [11C]CH. CONCLUSIONS: Our study favours a dual-tracer approach in HCC staging in high-risk patients or when conventional imaging is non-conclusive.
引用
- Veenstra EB, Ruiter SJS, de Haas RJ, et al. A dual-tracer approach using [11C]CH and [18F]FDG in HCC clinical decision making. EJNMMI Res. 2023. PMID: 37644167. doi:10.1186/s13550-023-01024-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。